FourThought Financial Partners LLC Takes Position in Pfizer Inc. (NYSE:PFE)

FourThought Financial Partners LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 31,692 shares of the biopharmaceutical company’s stock, valued at approximately $841,000.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Swedbank AB grew its position in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Pfizer by 7.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,742,343 shares of the biopharmaceutical company’s stock worth $50,423,000 after acquiring an additional 118,473 shares during the last quarter. Autumn Glory Partners LLC grew its position in shares of Pfizer by 126.2% during the third quarter. Autumn Glory Partners LLC now owns 30,250 shares of the biopharmaceutical company’s stock worth $875,000 after acquiring an additional 16,875 shares during the last quarter. Orrstown Financial Services Inc. bought a new position in shares of Pfizer during the third quarter worth about $427,000. Finally, Pallas Capital Advisors LLC grew its position in shares of Pfizer by 54.8% during the third quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after acquiring an additional 9,102 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $26.76 on Wednesday. The firm has a market cap of $151.62 billion, a PE ratio of 18.98, a PEG ratio of 0.64 and a beta of 0.64. The firm’s 50 day moving average price is $26.33 and its 200 day moving average price is $27.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.43%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PFE. Guggenheim reiterated a “buy” rating and issued a $33.00 target price on shares of Pfizer in a research report on Monday, February 10th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.